PF-4618433 is a potent and selective PYK2 inhibitor, with an IC 50 of 637 nM. PF-4618433 may be suitable for the research of osteoporosis, craniofacial and appendicular skeletal defects and for targeted bone regeneration In Vitro PF-4618433 (0.1-1.0 μM; 7 days) promotes osteogenesis of hMSC cultures. PF-4618433 increases in both alkaline phosphatase (ALP) activity and mineralization in a dependent manner. PF-4618433 (0.1-0.3 μM; 24 hours) enhances osteoblast proliferation. PF-4618433 (0.0125-0.3 μM; 14 or 21 days) enhances calcium deposition at the concentrations of 0.1 and 0.3 μM. MCE has not independently confirmed the accuracy of these methods. They are for reference only. Cell Proliferation AssayCell Line: Murine bone marrow-derived mesenchymal stem cells (BMSC) Concentration: 0.1, 0.3 μM Incubation Time: 24 hours Result: Increased cell proliferation activity significantly when compared to the untreated or control group. Form:Solid IC50& Target:IC50: 637 nM (PYK2)